Lijing Chen
About Lijing Chen
Lijing Chen is a Clinical Scientist with over 19 years of experience in drug discovery, particularly in oncology and virology. He has worked at Calithera Biosciences since 2016 and holds a Master of Science in Medicinal and Pharmaceutical Chemistry from the State University of New York at Buffalo.
Work at Calithera Biosciences
Lijing Chen has been a Clinical Scientist at Calithera Biosciences since 2020, contributing to drug discovery processes in oncology and virology. Prior to this role, Chen held several positions at the same organization, including Sr. Scientist I from 2018 to 2020, Scientist II from 2016 to 2018, and Scientist I from 2012 to 2016. Chen also served as Senior Research Associate II from 2010 to 2012. Throughout these roles, Chen has played a significant part in advancing multiple clinical candidates from early hits into clinical development.
Education and Expertise
Lijing Chen earned a Master of Science in Medicinal and Pharmaceutical Chemistry from the State University of New York at Buffalo, completing the program from 1999 to 2001. Chen also holds a Bachelor of Science in Pharmaceutical Sciences from the same university, obtained from 1994 to 1998. Chen has over 19 years of experience in the pharmaceutical industry, with a focus on drug discovery processes, particularly in oncology and virology. Chen has extensive training in Good Clinical Practice (GCP), enhancing expertise in clinical development.
Background
Lijing Chen began their career in the pharmaceutical industry at Roche, where they worked as a Research Associate II from 2005 to 2006 and later as a Research Associate III from 2006 to 2010 in Palo Alto, California. This experience laid the groundwork for Chen's extensive career in drug discovery, leading to various roles at Calithera Biosciences. Chen's academic background in pharmaceutical sciences supports a strong foundation in research and development within the industry.
Achievements
Throughout their career, Lijing Chen has successfully contributed to the development of multiple clinical candidates, advancing them from early hits into clinical development. This achievement reflects a deep understanding of the drug discovery process and a commitment to advancing therapeutic options in oncology and virology. Chen's work has been integral to the progress of clinical projects at Calithera Biosciences.